Mayo Clinic proceedings · 2016
Thrombotic Microangiopathy Care Pathway: A Consensus Statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group.
СтатьяПоддержка исследования: вне правительства СШАConsensus StatementНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Go Ronald S, Winters Jeffrey L, Leung Nelson, Murray David L, Willrich Maria A, Abraham Roshini S, Amer Hatem, Hogan William J, Marshall Ariela L, Sethi Sanjeev, Tran Cheryl L, Chen Dong, Pruthi Rajiv K, Ashrani Aneel A, Fervenza Fernando C, Cramer Carl H, Rodriguez Vilmarie, Wolanskyj Alexandra P, Thomé Stephan D, Hook C Christopher, Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy Disease-Oriented Group
Аннотация
Thrombotic microangiopathies (TMAs) comprise a heterogeneous set of conditions linked by a common histopathologic finding of endothelial damage resulting in microvascular thromboses and potentially serious complications. The typical clinical presentation is microangiopathic hemolytic anemia accompanied by thrombocytopenia with varying degrees of organ ischemia. The differential diagnoses are generally broad, while the workup is frequently complex and can be confusing. This statement represents the joint recommendations from a multidisciplinary team of Mayo Clinic physicians specializing in the management of TMA. It comprises a series of evidence- and consensus-based clinical pathways developed to allow a uniform approach to the spectrum of care including when to suspect TMA, what differential diagnoses to consider, which diagnostic tests to order, and how to provide initial empiric therapy, as well as some guidance on subsequent management.